OFS

OFS Capital Corp. 2025 Q3 Filing Summary

Business Context and Reporting Period

This summary covers the Quarterly Report on Form 10-Q for OFS Capital Corporation (OFS), a Business Development Company (BDC) and Regulated Investment Company (RIC). The reporting period ended September 30, 2025. OFS focuses on providing current income and capital appreciation primarily through debt investments in middle-market companies, with secondary exposure to equity and structured finance securities.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss on Investments: The company reported a net loss on investments of $7.8 million for Q3 2025, driven by a $4.6 million net realized loss and $3.1 million in net unrealized depreciation. This contrasts with a net loss of $1.9 million in Q3 2024.
• NAV Decline: NAV per share decreased from $10.91 at June 30, 2025, to $10.17 at September 30, 2025. The decline was primarily due to the net loss on investments and distributions ($0.34/share) exceeding net investment income ($0.22/share).
• Debt Refinancing: OFS refinanced $94.0 million of its 4.75% Unsecured Notes Due February 2026 by issuing $69.0 million of 7.50% Unsecured Notes Due July 2028 and a $25.0 million 8.00% Unsecured Note Due August 2029. This increased the weighted-average cost of debt.
• Non-Accrual Status: Loans to BayMark Health Services, Inc. (aggregate fair value $6.8 million) were placed on non-accrual status during the quarter. Total non-accrual loans stood at $23.1 million (6.2% of total investments) as of period end.
• BNP Facility Expiration: The reinvestment period for the BNP Facility expired on September 30, 2025, terminating the ability to access unused commitments or make new investments under this facility.

Guidance, Outlook, and Risks

• Dividend Policy: The Board declared a distribution of $0.17 per share for Q4 2025. Management estimates that a portion of 2025 distributions will be characterized as a return of capital.
• Liquidity Constraints: With the BNP Facility reinvestment period expired, short-term liquidity is constrained. The company relies on the Banc of California Credit Facility ($25.0 million unused commitment) and cash on hand ($5.0 million) to fund $18.3 million in unfunded portfolio commitments.
• Covenant Waiver: OFSCC-FS was not in compliance with certain BNP Facility provisions regarding collateral sales and over-collateralization ratios. A waiver agreement was executed on October 28, 2025, to waive these events of default.
• Interest Rate Risk: A 25 basis point reduction in the Federal Reserve target rate in September 2025 is expected to decrease interest income from variable-rate debt investments. Additionally, the recent refinancing to higher fixed rates may compress net interest margins.
• Valuation Risk: A significant portion of the portfolio (Level 3 assets) relies on unobservable inputs. The fair value of the Pfanstiehl Holdings, Inc. equity investment (57.6% of net assets) is subject to significant volatility and unrealized depreciation.

Investor Verification Checklist

• Verify the sustainability of the dividend given the Q3 distribution ($0.34) exceeded Net Investment Income ($0.22), resulting in a return of capital component.
• Monitor the status of the BNP Facility waiver and the company's ability to refinance or replace the facility upon its June 2027 maturity.
• Assess the impact of the $10.8 million unrealized depreciation on the Pfanstiehl Holdings, Inc. investment, which represents a significant concentration risk.
• Review the credit quality of the $23.1 million in non-accrual loans, specifically the restructuring of JP Intermediate B, LLC and the status of BayMark Health Services.
• Confirm the company's ability to meet the 150% asset coverage requirement under the 1940 Act as debt maturities approach (e.g., $31 million Unsecured Notes due Feb 2026).